Table 1.
Patient Characteristics.
| Total (n=150) | No Auto (FLU/TBI) (n=100) | Prior Auto (TBI only) (n=50) | |
|---|---|---|---|
| Patient age, median (range), years | 57 (20–74) | 60 (20–74) | 54 (28–70) |
| Male patient gender, no. (%) | 87 (58) | 54 (54) | 33 (66) |
| Donor age, median (range), years | 54 (23–76) | 57 (23–76) | 51 (24–68) |
| Sex of patient/donor | |||
| Male / Female, no. (%) | 41 (27) | 25 (25) | 16 (32) |
| Male / Male, no. (%) | 46 (31) | 29 (29) | 17 (34) |
| Female / Male, no. (%) | 23 (15) | 16 (16) | 7 (14) |
| Female / Female, no. (%) | 40 (27) | 30 (30) | 10 (20) |
| CMV serostatus of patient/donor | |||
| Negative/negative, no. (%) | 26 (17) | 20 (20) | 6 (12) |
| Negative/positive, no. (%) | 21 (14) | 15 (15) | 6 (12) |
| Positive/negative, no. (%) | 39 (26) | 26 (26) | 13 (26) |
| Positive/positive, no. (%) | 61 (41) | 37 (37) | 24 (48) |
| Positive/unknown, no. (%) | 3 (2) | 2 (2) | 1 (2) |
| Prior (failed) high-dose HCT | |||
| Autologous, no. (%) | 43 (29) | 281 (28) | 15 (29) |
| Allogeneic, no. (%) | 2 (1) | 2 (2) | 0 |
| Diagnoses | |||
| Acute myeloid leukemia, no. (%) | 42 (28) | 42 (42) | 0 |
| MDS/MPN, no. (%) | 12 (8) | 12 (12) | 0 |
| Acute lymphoblastic leukemia, no. (%) | 6 (4) | 6 (6) | 0 |
| Non-Hodgkin lymphoma, no. (%) | 25 (17) | 222 (22) | 3 (6) |
| Chronic lymphocytic leukemia, no. (%) | 2 (1) | 2 (2) | 0 |
| Hodgkin lymphoma, no. (%) | 8 (5) | 7 (7) | 1 (2) |
| Multiple myeloma, no. (%) | 55 (37) | 9 (9) | 46 (92) |
| Relapse risk (DRI) | |||
| Low, no. (%) | 14 (9) | 13 (13) | 1 (2) |
| Intermediate, no. (%) | 117 (78) | 71 (71) | 46 (92) |
| High/Very High, no. (%) | 19 (13) | 16 (16) | 3 (6) |
| HCT comorbidity index, no. (%) | |||
| 0 | 25 (17) | 15 (15) | 10 (20) |
| 1,2 | 36 (24) | 23 (23) | 13 (26) |
| 3+ | 87 (58) | 61 (61) | 26 (52) |
| unknown | 2 (1) | 1 (1) | 1 (2) |
| CD34+ dose, 106 cells kg, median (range) | 8.1 (1.0–25.3) | 8.1 (1.0–25.3) | 8.5 (3.1–22.2) |
| CD3+ dose, 108 cells/kg, median (range) | 3.5 (0.3–10.8) | 3.6 (0.3–10.2) | 3.5 (1.0–10.8) |
| Karnofsky performance status, no. (%) | |||
| 90–100 | 85 (57) | 51 (51) | 34 (68) |
| 80–85 | 35 (23) | 29 (29) | 6 (12) |
| 60–70 | 21 (14) | 18 (18) | 3 (6) |
| unknown | 9 (6) | 2 (2) | 7 (14) |
1
Includes two with multiple failed autos and 1 with prior auto for B-cell neoplasm transplanted for secondary MDS/AML
2
Includes two Waldenstrom’s disease
Abbreviations: FLU, fludarabine; TBI, total body irradiation; CMV, cytomegalovirus; HCT, hematopoietic cell transplant; MDS/MPD, myelodysplastic syndrome/myeloproliferative neoplasms; DRI, disease risk index